Volumetric FDG PET Analysis of Global Lung Inflammation: New Tool for Precision Medicine in Pulmonary Sarcoidosis?

Overview

Journal Sarcoidosis Vasc Diffuse Lung Dis

Specialties Allergy & Immunology
Cardiology & Vascular Diseases
Pulmonary Medicine

Date 2020 Jun 2

PMID 32476879

Citations 8

Authors

Human Adams

Rob van Rooij

Coline H M van Moorsel

Marcela Spee-Dropkova

Jan C Grutters

Ruth G Keijsers

Affiliations

Soon will be listed here.

Abstract

Currently FDG PET/CT is used as a tool for detection of active sites of sarcoidosis. Routine clinical practice relies on qualitative assessment with visual interpretation. When semi quantitatively expressed, e.g. for scientific purposes, this often leads to dichotomous "positive" or "negative" results. Metabolic activity in the lungs or mediastinum can also be expressed by SUVmax, but this measure is based only on the intensity of a single voxel. Likely for this reason these parameters show poor correlation with variables such as serum biomarkers and suboptimally predict clinical response to treatment. The current study focusses on new volumetric quantification methods for FDG PET/CT. Specifically the percentage of lung volume with increased metabolic activity, "%SUV-high", and the average metabolic activity in the lung "SUVmean", shows significantly better correlation with conventional biomarkers for disease activity than PET dichotomous and SUVmax. Our proposed quantification method needs subsequent and larger studies, however it may open new possibilities for future quantitative research in lung inflammation, and improve precision medicine in sarcoidosis. .

Citing Articles

Sarcoidosis-Associated Pulmonary Hypertension.

Morimatsu Y, Tahara N, Okamoto M, Bekki M, Tahara A, Eto Y Medicina (Kaunas). 2025; 61(2).

PMID: 40005458 PMC: 11857724. DOI: 10.3390/medicina61020342.

Emerging multimodality imaging techniques for the pulmonary circulation.

Rajagopal S, Bogaard H, Elbaz M, Freed B, Remy-Jardin M, van Beek E Eur Respir J. 2024; 64(4).

PMID: 39209480 PMC: 11525339. DOI: 10.1183/13993003.01128-2024.

Phenotypes of Sarcoidosis-Associated Pulmonary Hypertension-A Challenging Mystery.

Kacprzak A, Tomkowski W, Szturmowicz M Diagnostics (Basel). 2023; 13(19).

PMID: 37835874 PMC: 10572558. DOI: 10.3390/diagnostics13193132.

Sarcoidosis-associated pulmonary fibrosis: joining the dots.

Bandyopadhyay D, Mirsaeidi M Eur Respir Rev. 2023; 32(169).

PMID: 37758275 PMC: 10523156. DOI: 10.1183/16000617.0085-2023.

From Karl Wurm and Guy Scadding's staging to F-FDG PET/CT scan phenotyping and far beyond: perspective in the evading history of phenotyping in sarcoidosis.

Papiris S, Kolilekas L, Rivera N, Spanos M, Li G, Gokulnath P Front Med (Lausanne). 2023; 10:1174518.

PMID: 37234239 PMC: 10206027. DOI: 10.3389/fmed.2023.1174518.

References

Scadding J . Prognosis of intrathoracic sarcoidosis in England. A review of 136 cases after five years' observation. Br Med J. 1961; 2(5261):1165-72. PMC: 1970202. DOI: 10.1136/bmj.2.5261.1165. View

Ziora D, Kornelia K, Jastrzebski D, Labus L, Zieleznik K, Kozielski J . High resolution computed tomography in 2-year follow-up of Stage I sarcoidosis. Adv Exp Med Biol. 2013; 788:369-74. DOI: 10.1007/978-94-007-6627-3_50. View

. Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by.... Am J Respir Crit Care Med. 1999; 160(2):736-55. DOI: 10.1164/ajrccm.160.2.ats4-99. View

Rosen Y . Pathology of sarcoidosis. Semin Respir Crit Care Med. 2007; 28(1):36-52. DOI: 10.1055/s-2007-970332. View

Mostard R, Voo S, van Kroonenburgh M, Verschakelen J, Wijnen P, Nelemans P . Inflammatory activity assessment by F18 FDG-PET/CT in persistent symptomatic sarcoidosis. Respir Med. 2011; 105(12):1917-24. DOI: 10.1016/j.rmed.2011.08.012. View

Lee D, Kang H, Kim H, Park H, Oh J, Lee J . Metabolic connectivity by interregional correlation analysis using statistical parametric mapping (SPM) and FDG brain PET; methodological development and patterns of metabolic connectivity in adults. Eur J Nucl Med Mol Imaging. 2008; 35(9):1681-91. DOI: 10.1007/s00259-008-0808-z. View

Pak K, Cheon G, Nam H, Kim S, Kang K, Chung J . Prognostic value of metabolic tumor volume and total lesion glycolysis in head and neck cancer: a systematic review and meta-analysis. J Nucl Med. 2014; 55(6):884-90. DOI: 10.2967/jnumed.113.133801. View

Keijsers R, Verzijlbergen E, van den Bosch J, Zanen P, van de Garde E, Oyen W . 18F-FDG PET as a predictor of pulmonary function in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2011; 28(2):123-9. View

Mostard R, van Kuijk S, Verschakelen J, van Kroonenburgh M, Nelemans P, Wijnen P . A predictive tool for an effective use of (18)F-FDG PET in assessing activity of sarcoidosis. BMC Pulm Med. 2012; 12:57. PMC: 3509391. DOI: 10.1186/1471-2466-12-57. View

10.

Vorselaars A, Verwoerd A, van Moorsel C, Keijsers R, Rijkers G, Grutters J . Prediction of relapse after discontinuation of infliximab therapy in severe sarcoidosis. Eur Respir J. 2013; 43(2):602-9. DOI: 10.1183/09031936.00055213. View

11.

Sobic-Saranovic D, Grozdic I, Videnovic-Ivanov J, Vucinic-Mihailovic V, Artiko V, Saranovic D . The utility of 18F-FDG PET/CT for diagnosis and adjustment of therapy in patients with active chronic sarcoidosis. J Nucl Med. 2012; 53(10):1543-9. DOI: 10.2967/jnumed.112.104380. View

12.

Nardi A, Brillet P, Letoumelin P, Girard F, Brauner M, Uzunhan Y . Stage IV sarcoidosis: comparison of survival with the general population and causes of death. Eur Respir J. 2011; 38(6):1368-73. DOI: 10.1183/09031936.00187410. View

13.

Mostard R, Verschakelen J, van Kroonenburgh M, Nelemans P, Wijnen P, Voo S . Severity of pulmonary involvement and (18)F-FDG PET activity in sarcoidosis. Respir Med. 2012; 107(3):439-47. DOI: 10.1016/j.rmed.2012.11.011. View

14.

Nunes H, Brillet P, Valeyre D, Brauner M, Wells A . Imaging in sarcoidosis. Semin Respir Crit Care Med. 2007; 28(1):102-20. DOI: 10.1055/s-2007-970336. View

15.

Keijsers R, Verzijlbergen F, Oyen W, van den Bosch J, Ruven H, van Velzen-Blad H . 18F-FDG PET, genotype-corrected ACE and sIL-2R in newly diagnosed sarcoidosis. Eur J Nucl Med Mol Imaging. 2009; 36(7):1131-7. DOI: 10.1007/s00259-009-1097-x. View

16.

Adams H, Keijsers R, Korenromp I, Grutters J . FDG PET for gauging of sarcoid disease activity. Semin Respir Crit Care Med. 2014; 35(3):352-61. DOI: 10.1055/s-0034-1376866. View

17.

Chew H, Wun T, Harvey D, Zhou H, White R . Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med. 2006; 166(4):458-64. DOI: 10.1001/archinte.166.4.458. View

18.

de Rie M, Zonneveld I, Witkamp L, van Lier R, Out T, Bos J . Soluble interleukin-2 receptor (sIL-2R) is a marker of disease activity in psoriasis: a comparison of sIL-2R, sCD27, sCD4, sCD8 and sICAM-1. Acta Derm Venereol. 1996; 76(5):357-60. DOI: 10.2340/0001555576357360. View

19.

Yeo U, Yang Y, Park K, Sung H, Jung S, Lee E . Serum concentration of the soluble interleukin-2 receptor in vitiligo patients. J Dermatol Sci. 1999; 19(3):182-8. DOI: 10.1016/s0923-1811(98)00070-x. View

20.

Quanjer P, Tammeling G, Cotes J, Pedersen O, Peslin R, Yernault J . Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl. 1993; 16:5-40. View